Kevin Dunleavy

3 weeks ago | fiercepharma.com | Kevin Dunleavy

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing with Johnson & Johnson’s powerhouse Darzalex, largely because it reached the market five years later. But one advancement that could help Sanofi close some of the gap is its on-body delivery system for its CD38 antibody.

3 weeks ago | fiercepharma.com | Kevin Dunleavy

In late April, when Sanofi revealed that it was selling a controlling stake in its consumer health business Opella for 10 billion euros ($11.4 billion), chief financial officer Francois Roger said that the French drugmaker would “explore external growth opportunities for bolt-on acquisitions.”Just five weeks later, Sanofi has made a deal few would describe as “bolt-on,” as it has bought out Massachusetts-based Blueprint Medicines for up to $9.5 billion.

4 weeks ago | fiercepharma.com | Kevin Dunleavy

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to go through early next week. On Friday, private equity firms Carlyle and SK Capital revealed that they expect to complete the acquisition of bluebird on Monday. With an amended buyout agreement—bumping up their per-share offer from $3.00 to $5.00—Carlyle and SK have won the support of enough investors for the transaction to proceed.

4 weeks ago | fiercepharma.com | Ayla Ellison |Eric Sagonowsky |Kevin Dunleavy |Gabrielle Masson

Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week. On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still delivering strong sales growth despite emerging uncertainties in Washington, D.C., a few major players are starting to see a slowdown.

4 weeks ago | fiercepharma.com | Kevin Dunleavy

Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease (DED) treatment Tryptyr (acoltremon ophthalmic solution). Tryptyr, which is administered as a single drop twice daily, is a first-in-class TRPM8 receptor agonist intended to activate tear production.